Rapport Therapeutics, Inc. (RAPP) expects to raise $136 million in an initial public offering (IPO) on Friday, June 7th, IPO Scoop reports. The company will be issuing 8,000,000 shares at $16.00-$18.00 per share. Rapport Therapeutics, Inc. has a market cap of $601.4 million. Goldman Sachs, Jefferies, TD Cowen and Stifel served as the underwriters for […]
Rapport Therapeutics, Inc. (RAPP) expects to raise $136 million in an IPO on Friday, June 7th, IPO Scoop reports. The company will be issuing 8,000,000 shares at a price of $16.00-$18.00 per share. Rapport Therapeutics, Inc. has a market-cap of $601.4 million. Goldman Sachs, Jefferies, TD Cowen and Stifel served as the underwriters for the […]
Rapport Therapeutics, Inc. (RAPP) is planning to raise $136 million in an IPO on Friday, June 7th, IPO Scoop reports. The company plans to issue 8,000,000 shares at a price of $16.00-$18.00 per share. The company has a market-cap of $601.4 million. Goldman Sachs, Jefferies, TD Cowen and Stifel served as the underwriters for the […]
People use drugs for many reasons: they want to feel good, stop feeling bad, or perform better in school or at work, or they are curious because others are doing it and they want to fit in. The last reason is very common among teens.Drugs excite the parts of the brain that make you feel good.
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic.